ヘパリンの欧州市場:産業分析、市場規模、市場シェア、成長、動向、予測

◆英語タイトル:Heparin Market - Europe Industry Analysis, Size, Share, Growth, Trends, and Forecast 2016 - 2024
◆商品コード:TMR60947
◆発行会社(調査会社):Transparency Market Research
◆発行日:2016年8月29日
◆ページ数:101
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆調査対象地域:欧州
◆産業分野:産業未分類
◆販売価格オプション(消費税別)
Single UserUSD3,395 ⇒換算¥376,845見積依頼/購入/質問フォーム
Multi UserUSD4,395 ⇒換算¥487,845見積依頼/購入/質問フォーム
Corporate LicenseUSD5,395 ⇒換算¥598,845見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご確認ください。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(支払期限と方法は調整可能、振込先:三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はTransparency Market Research社の日本における正規販売代理店です。Transparency Market Research社の概要及び新刊レポートはこちらでご確認いただけます。
【レポートの概要】

This report provides in-depth country wise analysis of the heparin market in Europe. Stakeholders of this report include manufacturers of heparin products, crude heparin suppliers, heparin processing companies, and new players planning to enter the market.The report provides qualitative and quantitative analysis of the heparin market in Europe. Qualitative analysis comprises market dynamics, trends, product overview, and country-level market information. Quantitative analysis includes market share held by companies in 2015, market size, and forecast for the heparin market in major countries in Europe such as Germany, France, the U.K., Italy, Spain, Poland, Switzerland, Austria, Hungary, Belgium, Portugal, the Czech Republic, Greece, Slovakia, and Rest of Europe from 2014 to 2024. Market revenue is provided in terms of US$ Mn from 2014 to 2024 along with the compound annual growth rate (CAGR %) from 2016 to 2024 for all the segments, considering 2015 as the base year. The executive summary of the report provides a snapshot of the heparin market in Europe with information on leading segments, country wise market information with respect to the market size, growth rate (CAGR %), and growth factors.
The market overview section comprises impact factors such as drivers, restraints, and opportunities for the heparin market in Europe. These factors would aid the stakeholders in establishing a strong foothold in Europe. Furthermore, the market overview section comprises key industry events, product overview, mortality rate of CVD in Europe, leading causes of death, and country-wise pharmaceutical expenditure. The market attractiveness analysis provides a graphical view comparing the growth and market dynamics in various segments to identify the most attractive market.
Market share analysis is also provided in the competitive landscape section of the report for the year 2015 in terms of value (%). Furthermore, the report analyzes different heparin product types such as unfractionated heparin, low molecular weight heparin, and ultra-low molecular weight heparin. The product type section provides market analysis for different types of heparin in Europe. This includes an overview of product types, indications for use, presence of any biosimilars, market drivers, issues, and regulations amended for its production and use. Prices of products vary based on product type and formulation. Moreover, the heparin market by end-users such as hospitals, blood and stem cell banks, and others has also been analyzed in the report. The report provides average pricing analysis (based on the current prices) to offer an overview of prices of heparin-based pharmaceutical products in the EU (2015 & 2024).
The report provides market analysis for heparin in the major countries in the EU: Germany, France, the U.K., Italy, Spain, Poland, Switzerland, Austria, Hungary, Belgium, Portugal, the Czech Republic, Greece, Slovakia, and Rest of Europe. Market analysis for each of these countries has been provided from 2014 to 2024 along with the CAGR from 2016 to 2024. The market has been estimated for finished heparin formulation and has not considered its APIs. Major factors such as aging population and increasing prevalence of venous thromboembolism (VTE) that propel the market for heparin in Europe are elaborated in the report. This report also covers certain regulations governing the manufacture and import of heparin in some countries.
Major players operating in the heparin market in Europe such as Dr. Reddy’s Laboratories Ltd., Leo Pharma, Pfizer, Inc., Sanofi SA, and Teva Pharmaceutical Industries Ltd. are profiled in this report.
The Europe heparin market is segmented into the following categories:
Europe Heparin Market, by Product
• Unfractionated Heparin
• Low Molecular Weight Heparin
• Ultra-low Molecular Weight Heparin
Europe Heparin Market, by End-user
• Hospitals
• Blood and Stem Cell Banks
• Others
Europe Heparin Market, by Country
• Germany
• France
• U.K.
• Italy
• Spain
• Poland
• Switzerland
• Austria
• Hungary
• Belgium
• Portugal
• Czech Republic
• Greece
• Slovakia
• Rest of Europe

【レポートの目次】

1. Preface
1.1. Research Scope
1.2. Market Segmentation
1.3. Research Objectives
1.4. Key Questions Answered

2. Assumptions and Research Methodology
2.1. Report Assumptions
2.2. Acronyms Used
2.3. Research Methodology

3. Executive Summary
3.1. Europe Heparin Market Snapshot
3.2. Key Trends

4. Market Overview
4.1. Product Overview
4.2. Key Industry Events
4.3. Death Rate of CVD in Europe, 2015
4.4. Top Causes of Death in the EU
4.5. Pharmaceutical Expenditure, 2014
4.6. Pharmaceutical Expenditure, 2013

5. Market Dynamics
5.1. Drivers and Restraints Snapshot Analysis
5.2. Drivers
5.2.1. Rise in incidence of coagulation and renal disorders in Europe
5.2.2. Inclination of slaughterhouse owners to enter crude heparin processing business expected to overcome demand-supply gap
5.2.3. Ban on imports from China to boost production in Europe
5.2.4. Commercialization of safe and cost-effective heparin products
5.3. Restraints
5.3.1. Availability of alternative anticoagulants impeding sale of biological heparin products
5.3.2. Enhanced quality control measures and environmental factors elevating the cost of heparin production
5.3.3. Patent loss and increasing use of off-label products
5.3.4. Risk of heparin induced thrombocytopenia
5.4. Opportunities
5.4.1. Biosimilars as an alternative to biological-based products
5.4.2. Research activities on marine-based heparin products
5.5. Opportunity Analysis
5.6. Pricing and Market Projections

6. Europe Heparin Market Analysis, by Product Type
6.1. Key Findings
6.2. Market Value Share Analysis, by Product Type, 2015 and 2024
6.3. Europe Heparin Market Size (US$ Mn) Forecast, by Product, 2014-2024
6.3.1. Low Molecular Weight Heparin
6.3.2. Unfractionated Heparin
6.3.3. Ultra-low Molecular Weight Heparin
6.4. Key Trends
6.5. Market Attractiveness Analysis, by Product, 2015

7. Europe Heparin Market Analysis, by End-user
7.1. Key Findings
7.2. Introduction
7.3. Market Value Share Analysis, by End-user, 2015 and 2024
7.4. Europe Heparin Market Size (US$ Mn) Forecast, by End-user, 2014-2024
7.4.1. Hospitals
7.4.2. Blood and Stem Cell Bank
7.4.3. Others
7.5. Key Trends

8. Europe Heparin Market Analysis, by Country
8.1. Market Value Share Analysis, by Country, 2015 and 2024
8.2. Germany
8.3. France
8.4. U.K.
8.5. Italy
8.6. Spain
8.7. Poland
8.8. Switzerland
8.9. Austria
8.10. Hungary
8.11. Belgium
8.12. Portugal
8.13. Czech Republic
8.14. Greece
8.15. Slovakia
8.16. Rest of Europe
8.17. Market Attractiveness Analysis, by End-user, 2015

9. Competitive Landscape
9.1. Europe Heparin Market Share Analysis, by Company (2015)
9.2. Competition Matrix
9.2.1. Sanofi SA
9.2.2. GlaxoSmithKline plc
9.2.3. Pfizer, Inc.
9.2.4. Leo Pharma
9.2.5. Dr. Reddy’s Laboratories
9.2.6. Fresenius SE & Co. KG
9.2.7. Teva Pharmaceutical Industries Ltd.

10. Company Profiles
10.1. Sanofi SA
10.1.1. Company Details
10.1.2. Company Description
10.1.3. Business Overview
10.1.4. SWOT Analysis
10.1.5. Financial Analysis
10.1.6. Strategic Overview
10.2. GlaxoSmithKline plc
10.2.1. Company Details
10.2.2. Company Description
10.2.3. Business Overview
10.2.4. SWOT Analysis
10.2.5. Financial Analysis
10.2.6. Strategic Overview
10.3. Pfizer, Inc.
10.3.1. Company Details
10.3.2. Company Description
10.3.3. Business Overview
10.3.4. SWOT Analysis
10.3.5. Financial Analysis
10.3.6. Strategic Overview
10.4. Leo Pharma
10.4.1. Company Details
10.4.2. Company Description
10.4.3. Business Overview
10.4.4. SWOT Analysis
10.4.5. Financial Analysis
10.4.6. Strategic Overview
10.5. Dr. Reddy’s Laboratories
10.5.1. Company Details
10.5.2. Company Description
10.5.3. Business Overview
10.5.4. SWOT Analysis
10.5.5. Financial Analysis
10.5.6. Strategic Overview
10.6. Fresenius SE & Co. KG
10.6.1. Company Details
10.6.2. Company Description
10.6.3. Business Overview
10.6.4. SWOT Analysis
10.6.5. Financial Analysis
10.6.6. Strategic Overview
10.7. Teva Pharmaceutical Industries Ltd.
10.7.1. Company Details
10.7.2. Company Description
10.7.3. Business Overview
10.7.4. SWOT Analysis
10.7.5. Financial Analysis
10.7.6. Strategic Overview

List of Figures

FIG. 1 Europe Heparin Market Revenue (US$ Mn), 2015
FIG. 2 Europe Heparin Market Size (US$ Mn) Forecast, 2014–2024
FIG. 3 Europe Heparin Average Pricing Analysis (US$) 2015–2024
FIG. 4 Europe Heparin Market Value Share Analysis By Product, 2016 and 2024
FIG. 5 Europe LMWH Market Revenue, (US$ Mn), 2014-2024
FIG. 6 Europe Unfractionated Heparin Market Revenue (US$ Mn), 2014-2024
FIG. 7 Europe ULMWH Market Revenue, (US$ Mn), 2014-2024
FIG. 8 Europe Heparin Market Value Share Analysis By End-user, 2016 and 2024
FIG. 9 Europe Hospitals Heparin Market Revenue, (US$ Mn), 2014–2024
FIG. 10 Europe Blood and Stem Cell Bank Heparin Market Revenue, (US$ Mn), 2014-2024
FIG. 11 Europe Others (End-user) Heparin Market Revenue, (US$ Mn), 2014–2024
FIG. 12 Europe Heparin Market Value Share Analysis, by Country, 2015 and 2024
FIG. 13 Germany Heparin Market Revenue (US$ Mn), 2014–2024
FIG. 14 France Heparin Market Revenue (US$ Mn), 2014–2024
FIG. 15 UK Heparin Market Revenue (US$ Mn), 2014–2024
FIG. 16 Italy Heparin Market Revenue (US$ Mn), 2014–2024
FIG. 17 Spain Heparin Market Revenue (US$ Mn), 2014–2024
FIG. 18 Poland Heparin Market Revenue (US$ Mn), 2014–2024
FIG. 19 Switzerland Heparin Market Revenue (US$ Mn), 2014–2024
FIG. 20 Austria Heparin Market Revenue (US$ Mn), 2014–2024
FIG. 21 Hungary Heparin Market Revenue (US$ Mn), 2014–2024
FIG. 22 Belgium Heparin Market Revenue (US$ Mn), 2014–2024
FIG. 23 Portugal Heparin Market Revenue (US$ Mn), 2014–2024
FIG. 24 Czech Republic Heparin Market Revenue (US$ Mn), 2014–2024
FIG. 25 Greece Heparin Market Revenue (US$ Mn), 2014–2024
FIG. 26 Slovakia Heparin Market Revenue (US$ Mn), 2014–2024
FIG. 27 Rest of Europe Heparin Market Revenue (US$ Mn), 2014–2024
FIG. 28 Heparin Market Attractiveness Analysis, by Product, 2015
FIG. 29 Heparin Market Attractiveness Analysis, by End-user, 2015
FIG. 30 Europe Heparin Market Share Analysis By Company (2015)

List of Tables

TABLE 1 Europe Heparin Market Size (US$ Mn) Forecast, By Product, 2016–2024
TABLE 2 Europe Heparin Market Size (US$ Mn) Forecast, By End-user, 2016–2024
TABLE 3 Europe Heparin Market Size (US$ Mn) Forecast, by Country, 2014–2024



【レポートのキーワード】

ヘパリン、低分子ヘパリン、未分画ヘパリン、超低分子ヘパリン

★調査レポート[ヘパリンの欧州市場:産業分析、市場規模、市場シェア、成長、動向、予測]販売に関する免責事項
★調査レポート[ヘパリンの欧州市場:産業分析、市場規模、市場シェア、成長、動向、予測]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆